GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 112 participants.

Also called NCT06827990

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 112 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06827990
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06827990. Non-randomized; no masking; primary purpose treatment. Start 2025-09-22 (actual); primary completion 2030-09-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections
Acronym
ARISE III
Intervention (Device)
GORE® Ascending Stent Graft (ASG device)
Lead sponsor
W.L.Gore & Associates (class: industry)

Record details

Record id
cardio:ct-nct06827990
Content hash
265f6cf3fd97b65c34470cc84aac7f5e325a4a0153849a83b3aba16065bfee9b